The current endeavors to understand the pathogenesis of intractable liver diseases

Tohoku Journal of Experimental Medicine

Volumn 226, Issue 3, 2012, Pages 171-175

  Ueno, Yoshiyuki ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Fulminant hepatitis; Hepatitis B virus; Intractable liver diseases; Liver failure; Primary biliary cirrhosis

Indexed keywords

COMPLEMENTARY DNA; IMMUNOGLOBULIN M; MITOCHONDRION ANTIBODY;

CLINICAL FEATURE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; REVIEW;

COMORBIDITY; END STAGE LIVER DISEASE; FEMALE; HEPATITIS B; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULIN M; LIVER CIRRHOSIS, BILIARY; MALE; SEX FACTORS;

EID: 84857301711     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.226.171     Document Type: Review

References (36)

1. Alpini, G., Roberts, S., Kuntz, S.M., Ueno, Y., Gubba, S., Podila, P.V., LeSage, G. & LaRusso, N.F. (1996) Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. Gastroenterology, 110, 1636-1643.
2. Alpini, G., Ueno, Y., Glaser, S.S., Marzioni, M., Phinizy, J.L., Francis, H. & Lesage, G. (2001) Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes. Hepatology, 34, 868-876.
3. Alpini, G., Ulrich, C., Roberts, S., Phillips, J.O., Ueno, Y., Podila, P.V., Colegio, O., LeSage, G.D., Miller, L.J. & LaRusso, N.F. (1997) Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am. J. Physiol., 272, G289-297.
4. Amarapurkar, D., Han, K.H., Chan, H.L. & Ueno, Y. (2009) Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J. Gastroenterol. Hepatol., 24, 955-961.
5. Chuang, Y.H., Ridgway, W.M., Ueno, Y. & Gershwin, M.E. (2008) Animal models of primary biliary cirrhosis. Clin. Liver Dis., 12, 333-347.
6. Fukushima, K., Ueno, Y. & Shimosegawa, T. (2010) Treatment of Primary Biliary Cirrhosis: A new challenge? Hepatol. Res., 40, 61-68.
7. Inoue, J., Ueno, Y., Kanno, N., Anzai, H., Kondo, Y., Moritoki, Y., Mikami, E., Chiba, M., Kogure, T., Nagasaki, F., Fukushima, K., Iwasaki, T., Satomi, S. & Shimosegawa, T. (2005) Living related liver transplantation for acute fulminant hepatitis B: experience from two possible hyper-acute cases. Tohoku J. Exp. Med., 205, 197-204.
8. Inoue, J., Ueno, Y., Nagasaki, F., Wakui, Y., Kondo, Y., Fukushima, K., Niitsuma, H. & Shimosegawa, T. (2009) Enhanced intracellular retention of a hepatitis B virus strain associated with fulminant hepatitis. Virology, 395, 202-209.
9. Inoue, J., Ueno, Y. & Shimosegawa, T. (2011a) Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues. Indian. J. Med. Res., 133, 11-14.
10. Inoue, J., Ueno, Y., Wakui, Y., Fukushima, K., Kondo, Y., Kakazu, E., Ninomiya, M., Niitsuma, H. & Shimosegawa, T. (2011b) Enhanced replication of hepatitis B virus with frameshift in the precore region found in fulminant hepatitis patients. J. Infect. Dis., 204, 1017-1025.
11. Inoue, J., Ueno, Y., Wakui, Y., Niitsuma, H., Fukushima, K., Yamagiwa, Y., Shiina, M., Kondo, Y., Kakazu, E., Tamai, K., Obara, N., Iwasaki, T. & Shimosegawa, T. (2011c) Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J. Viral. Hepat., 18, 206-215.
12. Kakazu, E., Ueno, Y., Kondo, Y., Fukushima, K., Shiina, M., Inoue, J., Tamai, K., Ninomiya, M. & Shimosegawa, T. (2009) Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology, 50, 1936-1945.
13. Kakazu, E., Ueno, Y., Kondo, Y., Inoue, J., Ninomiya, M., Kimura, O., Wakui, Y., Fukushima, K., Tamai, K. & Shimosegawa, T. (2011) Plasma L-Cystine/L-Glutamate Imbalance Increases Tumor Necrosis Factor-Alpha from CD14+ Circulating Monocytes in Patients with Advanced Cirrhosis. PLoS One, 6, e23402.
14. Kido, O., Fukushima, K., Ueno, Y., Inoue, J., Jefferson, D.M. & Shimosegawa, T. (2009) Compensatory role of inducible annexin A2 for impaired biliary epithelial anion-exchange activity of inflammatory cholangiopathy. Lab. Invest., 89, 1374-1386.
15. Kogure, T., Ueno, Y., Fukushima, K., Nagasaki, F., Kondo, Y., Inoue, J., Matsuda, Y., Kakazu, E., Yamamoto, T., Onodera, H., Miyazaki, Y., Okamoto, H., Akahane, T., Kobayashi, T., Mano, Y., Iwasaki, T., Ishii, M. & Shimosegawa, T. (2008) Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J. Gastroenterol., 14, 7225-4230.
16. Kumada, H., Okanoue, T., Onji, M., Moriwaki, H., Izumi, N., Tanaka, E., Chayama, K., Sakisaka, S., Takehara, T., Oketani, M., Suzuki, F., Toyota, J., Nomura, H., Yoshioka, K., Seike, M., Yotsuyanagi, H. & Ueno, Y. (2010a) Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol. Res., 40, 1-7.
17. Kumada, H., Okanoue, T., Onji, M., Moriwaki, H., Izumi, N., Tanaka, E., Chayama, K., Sakisaka, S., Takehara, T., Oketani, M., Suzuki, F., Toyota, J., Nomura, H., Yoshioka, K., Seike, M., Yotsuyanagi, H. & Ueno, Y. (2010b) Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol. Res., 40, 8-13.
18. Lesage, G., Glaser, S., Ueno, Y., Alvaro, D., Baiocchi, L., Kanno, N., Phinizy, J.L., Francis, H. & Alpini, G. (2001) Regression of cholangiocyte proliferation after cessation of ANIT feeding is coupled with increased apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol., 281, G182-190.
19. Mikami, E., Kanno, N., Ueno, Y. & Shimosegawa, T. (2007) Retrospective evaluation of tumor-mass-reduction therapy for the prognosis of recurrent hepatocellular carcinoma. Hepatol. Int., 1, 460-469.
20. Moritoki, Y., Lian, Z.X., Lindor, K., Tuscano, J., Tsuneyama, K., Zhang, W., Ueno, Y., Dunn, R., Kehry, M., Coppel, R.L., Mackay, I.R. & Gershwin, M.E. (2009a) B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology, 50, 1893-1903.
21. Moritoki, Y., Lian, Z.X., Wulff, H., Yang, G.X., Chuang, Y.H., Lan, R.Y., Ueno, Y., Ansari, A.A., Coppel, R.L., Mackay, I.R. & Gershwin, M.E. (2007) AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology, 45, 314-322.
22. Moritoki, Y., Zhang, W., Tsuneyama, K., Yoshida, K., Wakabayashi, K., Yang, G.X., Bowlus, C., Ridgway, W.M., Ueno, Y., Ansari, A.A., Coppel, R.L., Mackay, I.R., Flavell, R.A., Gershwin, M.E. & Lian, Z.X. (2009b) B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology, 136, 1037-1047.
23. Nagasaki, F., Ueno, Y., Niitsuma, H., Inoue, J., Kogure, T., Fukushima, K., Kobayashi, K. & Shimosegawa, T. (2008) Analysis of the entire nucleotide sequence of hepatitis B causing consecutive cases of fatal fulminant hepatitis in Miyagi Prefecture Japan. J. Med. Virol., 80, 967-973.
24. Nakagome, Y., Ueno, Y., Kogure, T., Fukushima, K., Moritoki, Y., Ridgway, W.M., Eric Gershwin, M. & Shimosegawa, T. (2007) Autoimmune cholangitis in NOD.c3c4 mice is associated with cholangiocyte-specific Fas antigen deficiency. J. Autoimmun., 29, 20-29.
25. Ninomiya, M., Ueno, Y. & Shimosegawa, T. (2012) PBC: animal models of cholangiopathies and possible endogenous viral infections. Int. J. Hepatol., 2012, 649290.
26. Obara, N., Fukushima, K., Ueno, Y., Wakui, Y., Kimura, O., Tamai, K., Kakazu, E., Inoue, J., Kondo, Y., Ogawa, N., Sato, K., Tsuduki, T., Ishida, K. & Shimosegawa, T. (2010) Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J. Hepatol., 53, 326-334.
27. Poupon, R.E., Lindor, K.D., Cauch-Dudek, K., Dickson, E.R., Poupon, R. & Heathcote, E.J. (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology, 113, 884-890.
28. Roberts, S.K., Yano, M., Ueno, Y., Pham, L., Alpini, G., Agre, P. & LaRusso, N.F. (1994) Cholangiocytes express the aquaporin CHIP and transport water via a channel-mediated mechanism. Proc. Natl. Acad. Sci. USA, 91, 13009-13013.
29. Tamai, K., Fukushima, K., Ueno, Y., Moritoki, Y., Yamagiwa, Y., Kanno, N., Jefferson, D.M. & Shimosegawa, T. (2006) Differential expressions of aquaporin proteins in human cholestatic liver diseases. Hepatol. Res., 34, 99-103.
30. Ueno, Y., Alpini, G., Yahagi, K., Kanno, N., Moritoki, Y., Fukushima, K., Glaser, S., LeSage, G. & Shimosegawa, T. (2003) Evaluation of differential gene expression by microarray analysis in small and large cholangiocytes isolated from normal mice. Liver Int., 23, 449-459.
31. Ueno, Y., Ambrosini, Y.M., Moritoki, Y., Ridgway, W.M. & Gershwin, M.E. (2010) Murine models of autoimmune cholangitis. Curr. Opin. Gastroenterol., 26, 274-279.
32. Ueno, Y., Ishii, M., Yahagi, K., Mano, Y., Kisara, N., Nakamura, N., Shimosegawa, T., Toyota, T. & Nagata, S. (2000) Fasmediated cholangiopathy in the murine model of graft versus host disease. Hepatology, 31, 966-974.
33. Ueno, Y., Moritoki, Y., Shimosegawa, T. & Gershwin, M.E. (2007) Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models. J. Gastroenterol., 42, 189-195.
34. Ueno, Y., Phillips, J.O., Ludwig, J., Lichtman, S.N. & LaRusso, N.F. (1996) Development and characterization of a rodent model of immune-mediated cholangitis. Proc. Natl. Acad. Sci. USA, 93, 216-220.
35. Ueno, Y., Sollano, J.D. & Farrell, G.C. (2009) Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J. Gastroenterol. Hepatol., 24, 531-536.
36. Xu, L., Shen, Z., Guo, L., Fodera, B., Keogh, A., Joplin, R., O'Donnell, B., Aitken, J., Carman, W., Neuberger, J. & Mason, A. (2003) Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc. Natl. Acad. Sci. USA, 100, 8454-8459.